Skip to main
JNJ
JNJ logo

JNJ Stock Forecast & Price Target

JNJ Analyst Ratings

Based on 29 analyst ratings
Buy
Strong Buy 31%
Buy 21%
Hold 48%
Sell 0%
Strong Sell 0%

Bulls say

Johnson & Johnson has experienced a notable acceleration in its revenue growth, increasing from 3–4% in the 2016–2019 period to 6.1% in 2022 and 7.8% in 2023, reflecting the company's successful focus on innovation and productivity. The company’s pharmaceutical division, bolstered by an expanding product pipeline, particularly in immunology and oncology, is expected to contribute to sustained revenue growth as indicated by high clinical remission rates from its therapies. Additionally, Johnson & Johnson remains attractively valued, trading in line with historical multiples despite its enhanced financial profile following the divestment of its consumer business.

Bears say

Johnson & Johnson's stock outlook appears negative primarily due to several critical factors impacting its future revenue potential. The company faces a significant risk from loss of exclusivity on key drugs, which could result in lower-than-expected organic revenue growth, and concerns regarding the uptake of MedTech products amidst competitive pressures. Additionally, ongoing litigations and the financial implications of the Inflation Reduction Act present further risks that could hinder performance and disrupt operations, complicating its path for sustainable growth in the near future.

JNJ has been analyzed by 29 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 21% recommend Buy, 48% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Johnson & Johnson (JNJ) Forecast

Analysts have given JNJ a Buy based on their latest research and market trends.

According to 29 analysts, JNJ has a Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $159.21, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $159.21, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Johnson & Johnson (JNJ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.